Physician profile
David C Semler
NPI 1063470078
$12,325.00
in general payments reported to CMS, 2019-2025
45 companies · $2,563 in 2025
The $2,563 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,896 · 2020: $911 · 2021: $1,596 · 2022: $1,545 · 2023: $1,838 · 2024: $1,976 · 2025: $2,563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,083 · Education: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,083.18 |
| Education | $293.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,048.90 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Janssen Biotech, INC. | $1,351.23 | 2019-2025 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,250.53 | 2019-2025 | Cabtreo, Arazlo, Altreno |
| Incyte Corporation | $832.31 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $622.95 | 2019-2025 | |
| Galderma Laboratories, L.P. | $606.35 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Amgen INC. | $534.93 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $472.29 | 2019-2025 | Ilumya, Blu-U, Odomzo |
| Regeneron Healthcare Solutions, INC. | $453.61 | 2019-2025 | Dupixent |
| Pfizer INC. | $453.59 | 2019-2025 | |
| Ucb, INC. | $405.08 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $372.71 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $363.30 | 2019-2025 | |
| Dermavant Sciences, INC. | $329.15 | 2023-2024 | Vtama |
| Leo Pharma INC. | $232.33 | 2019-2025 | Adbry |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $228.15 | 2020-2021 | |
| Celgene Corporation | $186.96 | 2019-2023 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.07 | 2022-2025 | Spevigo, Cyltezo |
| Arcutis Biotherapeutics, INC. | $134.84 | 2023-2025 | Zoryve |
| Organogenesis INC. | $121.11 | 2021-2025 | Puraply, Via Matrix, Cygnus Dual |
| Convatec INC. | $103.65 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $96.00 | 2022 | |
| Mayne Pharma Commercial LLC | $93.62 | 2019-2022 | |
| Genentech USA, INC. | $90.93 | 2021-2024 | Erivedge |
| E.R. Squibb & Sons, L.L.C. | $79.57 | 2022-2024 | Sotyktu |
| Fresenius Kabi USA, LLC | $70.69 | 2023 | Idacio |
| Journey Medical Corporation | $57.29 | 2022-2023 | |
| Prugen, INC. Pharmaceuticals | $55.99 | 2019-2020 | |
| Almirall LLC | $55.13 | 2019-2023 | Seysara |
| Allergan, INC. | $52.03 | 2019-2021 | |
| Mimedx Group, INC. | $49.98 | 2024-2025 | |
| Kyowa Kirin, INC. | $49.39 | 2022-2025 | Poteligeo |
| Biofrontera INC. | $46.80 | 2021-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Helsinn Therapeutics (U.S.), INC. | $46.50 | 2022-2023 | Valchlor |
| Kerecis Limited | $41.14 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Epi Health, LLC | $29.31 | 2019-2020 | |
| Promius Pharma LLC | $20.26 | 2019 | |
| Organon LLC | $20.05 | 2025 | Vtama |
| Aclaris Therapeutics, INC. | $19.37 | 2019 | |
| Paratek Pharmaceuticals, INC. | $15.91 | 2021 | |
| Lnhc, INC | $15.69 | 2025 | Zelsuvmi |
| Dusa Pharmaceuticals, INC. | $13.25 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Dermira, INC. | $12.92 | 2020 | |
| Sandoz INC. | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Semler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.